Oral semaglutide and kidney outcomes in type 2 diabetes: A prespecified analysis of the SOUL randomised cardiovascular outcomes trial
Authors:
Johannes F. E. Mann1; Nikolaus Marx2; John E. Deanfield3; Scott Emerson4; Silvio E. Inzucchi5; Darren K. McGuire6; Sharon L. Mulvagh7; Rodica Pop-Busui8; Neil Poulter9; Kirstine Brown-Frandsen10; Mads D. Engelmann10; G. Kees Hovingh10; Nicolas Belmar10; Thomas Idorn10; Ole Kleist Jeppesen10; Andreas L. Birkenfeld11; Aslam Amod12; Boris Mankovsky13; Cyrus Desouza14; Juan Jose Gorgojo Martinez15; Rosario Arechavaleta16; Shih Te Tu17; John B. Buse18; on behalf of the SOUL Study Group